Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
December 12, 2025
1st Circ. OKs Barring Medicaid Planned Parenthood Coverage
A First Circuit panel on Friday upheld the Trump administration's ban on Medicaid funding for Planned Parenthood, vacating a lower court's order that would've kept in place Medicaid reimbursements for Planned Parenthood clinics in 22 states.
-
December 12, 2025
Ore. Justices Rule Docs Can Be Liable For Nonpatient Deaths
Oregon's highest court ruled that medical professionals can be held liable if their negligence results in a nonpatient's death, settling a split between a trial and appeals court in a case over a cyclist struck and killed by a driver under the influence of prescription drugs.
-
December 12, 2025
Squires Institutes 7 AIA Reviews, Denies 12 Other Petitions
U.S. Patent and Trademark Office Director John Squires has instituted seven America Invents Act reviews in the second round of cases where he has found that patent challenges warrant consideration since taking over the institution process.
-
December 12, 2025
CooperSurgical Escapes Repeat Filshie Clip Claims In Conn.
Medical device maker CooperSurgical Inc. has scored a quick win on some women's claims that the Filshie Clip, a coated titanium birth control device, detached and migrated within their bodies, with a Connecticut state judge finding certain plaintiffs could not advance cases similar to claims they lost elsewhere.
-
December 12, 2025
Next Steps For Orgs. Amid Updated OpenAI Usage Policies
OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals